Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. 2009

Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
Department of Medicine, Surgery and Dentistry, Division of Pathology, University of Milan, AO S Paolo e Fondazione IRCCS Ospedale Maggiore Policlinico, Regina Elena e Mangiagalli, Milan, Italy. claudia.augello@unimi.it

BACKGROUND Similarly to other tumor types, an imbalance between unrestrained cell proliferation and impaired apoptosis appears to be a major unfavorable feature of hepatocellular carcinoma (HCC). The members of IAP family are key regulators of apoptosis, cytokinesis and signal transduction. IAP survival action is antagonized by specific binding of Smac/DIABLO and XAF1. This study aimed to investigate the gene and protein expression pattern of IAP family members and their antagonists in a series of human HCCs and to assess their clinical significance. METHODS Relative quantification of IAPs and their antagonist genes was assessed by quantitative Real Time RT-PCR (qPCR) in 80 patients who underwent surgical resection for HCC. The expression ratios of XIAP/XAF1 and of XIAP/Smac were also evaluated. Survivin, XIAP and XAF1 protein expression were investigated by immunohistochemistry. Correlations between mRNA levels, protein expression and clinicopathological features were assessed. Follow-up data were available for 69 HCC patients. The overall survival analysis was estimated according to the Kaplan-Meier method. RESULTS Survivin and Livin/ML-IAP mRNAs were significantly over-expressed in cancer tissues compared to non-neoplastic counterparts. Although Survivin immunoreactivity did not correlate with qPCR data, a significant relation was found between higher Survivin mRNA level and tumor stage, tumor grade and vascular invasion.The mRNA ratio XIAP/XAF1 was significantly higher in HCCs than in cirrhotic tissues. Moreover, high XIAP/XAF1 ratio was an indicator of poor prognosis when overall survival was estimated and elevated XIAP immunoreactivity was significantly associated with shorter survival. CONCLUSIONS Our study demonstrates that alterations in the expression of IAP family members, including Survivin and Livin/ML-IAP, are frequent in HCCs. Of interest, we could determine that an imbalance in XIAP/XAF1 mRNA expression levels correlated to overall patient survival, and that high XIAP immunoreactivity was a poor prognostic factor.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008869 Microtubule-Associated Proteins High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules. Ensconsin,Epithelial MAP, 115 kDa,Epithelial Microtubule-Associate Protein, 115 kDa,MAP4,Microtubule Associated Protein,Microtubule Associated Protein 4,Microtubule Associated Protein 7,Microtubule-Associated Protein,Microtubule-Associated Protein 7,E-MAP-115,MAP1 Microtubule-Associated Protein,MAP2 Microtubule-Associated Protein,MAP3 Microtubule-Associated Protein,Microtubule Associated Proteins,Microtubule-Associated Protein 1,Microtubule-Associated Protein 2,Microtubule-Associated Protein 3,7, Microtubule-Associated Protein,Associated Protein, Microtubule,E MAP 115,Epithelial Microtubule Associate Protein, 115 kDa,MAP1 Microtubule Associated Protein,MAP2 Microtubule Associated Protein,MAP3 Microtubule Associated Protein,Microtubule Associated Protein 1,Microtubule Associated Protein 2,Microtubule Associated Protein 3,Microtubule-Associated Protein, MAP1,Microtubule-Associated Protein, MAP2,Microtubule-Associated Protein, MAP3,Protein 7, Microtubule-Associated,Protein, Microtubule Associated,Protein, Microtubule-Associated
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas

Related Publications

Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
April 2008, Cell cycle (Georgetown, Tex.),
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
August 2022, Asia-Pacific journal of clinical oncology,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
December 2009, Journal of translational medicine,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
January 2021, International journal of clinical and experimental pathology,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
April 2013, Korean journal of pathology,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
October 2017, Oncotarget,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
June 2016, Oncology letters,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
December 1998, Oncogene,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
November 2015, Biochemical and biophysical research communications,
Claudia Augello, and Luca Caruso, and Marco Maggioni, and Matteo Donadon, and Marco Montorsi, and Roberto Santambrogio, and Guido Torzilli, and Valentina Vaira, and Caterina Pellegrini, and Massimo Roncalli, and Guido Coggi, and Silvano Bosari
August 2017, Oncotarget,
Copied contents to your clipboard!